MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma
Year: 2022
Type: conference-abstract
Authors: Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, Jason Brayer, James E. Hoffman, William I. Bensinger, Ka Lung Wu, Linzhi Xu, Dhruti Chokshi, Anita Boyapati, Damien Cronier, Yariv Houvras, Karen Rodriguez Lorenc, Glenn S. Kroog, Madhav V. Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath
Institutions: The Barbara Ann Karmanos Cancer Institute, Icahn School of Medicine at Mount Sinai, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Moffitt Cancer Center, University of Miami Health System, Ziekenhuisnetwerk Antwerpen Stuivenberg, Regeneron (United States), Emory University, Columbia University Irving Medical Center, Rutgers, The State University of New Jersey, Rutgers Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4296532273